Receiving a diagnosis of endocarditis can be a deeply unsettling experience. This infection of the heart’s inner lining and valves typically starts with vague, flu-like symptoms but can rapidly escalate, causing severe fatigue, aching joints, and shortness of breath. The condition places the heart under immense stress and carries the risk of damaging the delicate valves that control blood flow. Immediate and aggressive treatment is necessary not only to relieve these frightening symptoms but to prevent life-threatening complications such as heart failure or stroke caused by clumps of bacteria breaking off and traveling to other parts of the body. 

Because endocarditis is almost always caused by bacteria entering the bloodstream, the core of the treatment plan is eradicating the infection. The specific approach depends entirely on which bacteria or fungus is causing the infection and whether the patient has an artificial or natural heart valve. Treatment is intense and typically requires a hospital stay to ensure the infection is fully cleared from the bloodstream and heart tissue (American Heart Association, 2024). 

Overview of treatment options for Endocarditis 

The primary goal of treating endocarditis is to completely eliminate the microorganism causing the infection. Unlike minor infections that can be treated with a short course of pills, endocarditis requires high doses of intravenous (IV) antibiotics administered over several weeks. This prolonged course is necessary because bacteria can “hide” within the vegetation (clumps of cells and germs) on the heart valves, making them difficult to reach. 

While medication is the first line of defense, surgery is required in a significant number of cases. If the infection has severely damaged a heart valve, caused a large abscess, or if the risk of stroke is high, doctors may recommend surgery to repair or replace the valve and mechanically remove the infected tissue. However, almost all treatment plans begin with aggressive medication therapy to stabilize the patient. 

Medications used for Endocarditis 

Doctors rely on potent antibiotics to fight this infection. The choice of drug is initially broad but becomes specific once lab cultures identify the exact bacteria. 

  • Penicillins are frequently used as a first-line treatment for infections caused by streptococci, bacteria often found in the mouth. Medications like penicillin G or ampicillin are standard. These are often potent and effective for native valve infections. 
  • Cephalosporins, such as ceftriaxone, are often prescribed when patients cannot tolerate penicillin or when the bacteria are susceptible to this class. Clinical experience suggests these are particularly useful for outpatient therapy once the patient is stable because some can be dosed once daily. 
  • Glycopeptides, like vancomycin, are the standard treatment for staph infections or for penicillin-allergic patients. Vancomycin is vital for treating methicillin-resistant Staphylococcus aureus (MRSA). 
  • Aminoglycosides (e.g., gentamicin) are rarely used alone, but combined with penicillin or vancomycin for a synergistic effect that more rapidly clears bacterial infection.  
  • Antifungals (e.g., amphotericin B) treat rare fungal infections and often require long-term administration followed by lifelong oral suppression. 

How these medications work 

The medications used for endocarditis function by dismantling the structure of the invading pathogen. 

Penicillins, cephalosporins, and glycopeptides are cell wall inhibitors. They weaken the bacterial outer wall, causing the bacteria to become unstable and burst.  

Aminoglycosides enter the bacterial cell and block protein production essential for growth and repair. When combined with cell wall inhibitors, the latter facilitates the aminoglycoside’s entry to internally shut down the cell. 

Side effects and safety considerations 

Because endocarditis treatment involves high doses of strong medications over a long period, side effects are a key consideration. 

Vancomycin and gentamicin require close kidney function monitoring due to potential toxicity; high levels risk kidney damage. Gentamicin also poses a risk of hearing or balance issues. Doctors use blood tests to ensure safe, effective dosing. 

Penicillins or cephalosporins can cause allergic reactions, from mild rashes to severe anaphylaxis. Patients must report itching or swelling immediately. Long-term IV use also risks catheter complications like local irritation or infection. 

Immediate medical attention is needed for returning fever, severe headache, or sudden facial or limb weakness, as these may signal a stroke or worsening infection (Mayo Clinic, 2023). 

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care. 

References 

  1. American Heart Association. https://www.heart.org 
  1. Mayo Clinic. https://www.mayoclinic.org 
  1. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov 
  1. MedlinePlus. https://medlineplus.gov 

Medications for Endocarditis

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Endocarditis.

Found 7 Approved Drugs for Endocarditis

Dapzura

Generic Name
Daptomycin

Dapzura

Generic Name
Daptomycin
Staphylococcus aureus Bloodstream Infections (Bacteremia), in Adult Patients, Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates Daptomycin for Injection is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia), including adult patients with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. Pediatric use information is approved for Merck & Co., Inc.’s Cubicin (daptomycin for injection). However, due to Merck & Co., Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Complicated Skin and Skin Structure Infections (cSSSI) Daptomycin for Injection is indicated for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only). Pediatric use information is approved for Merck & Co., Inc.’s Cubicin (daptomycin for injection). However, due to Merck & Co., Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Daptomycin for Injection is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) in adult patients. Limitations of Use Daptomycin for Injection is not indicated for the treatment of pneumonia. Daptomycin for Injection is not indicated for the treatment of left-sided infective endocarditis due to S.aureus. The clinical trial of Daptomycin for Injection in adult patients with S. aureus bloodstream infections included limited data from patients with left-sided infective endocarditis; outcomes in these patients were poor [ see Clinical Studies ( 1. Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to daptomycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Daptomycin for Injection and other antibacterial drugs, Daptomycin for Injection should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information is available, it should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Empiric therapy may be initiated while awaiting test results.

CeFAZolin

Generic Name
CeFAZolin

CeFAZolin

Generic Name
CeFAZolin
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefazolin for Injection, USP is indicated for the treatment of the following serious infections due to susceptible organisms. Cefazolin for Injection, USP is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible isolates of the designated microorganisms: Respiratory tract infections.

Primaxin

Generic Name
Imipenem

Primaxin

Generic Name
Imipenem
Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections.

Ancobon

Generic Name
Flucytosine

Ancobon

Generic Name
Flucytosine
Flucytosine Capsules USP is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus. Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules USP should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules USP (See MICROBIOLOGY ).

Mycamine

Generic Name
Micafungin

Mycamine

Generic Name
Micafungin
Micafungin in Sodium Chloride Injection is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older for whom appropriate dosing with this formulation can be achieved [ see Clinical Studies (1.
Showing 1-5 of 7
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances